PT - JOURNAL ARTICLE AU - Saqib Mumtaz AU - Jason Goh AU - Gideon M Hirschfield AU - James Ferguson AU - Sheldon C Cooper TI - Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab AID - 10.1136/flgastro-2016-100711 DP - 2016 Oct 01 TA - Frontline Gastroenterology PG - 271--274 VI - 7 IP - 4 4099 - http://fg.bmj.com/content/7/4/271.short 4100 - http://fg.bmj.com/content/7/4/271.full SO - Frontline Gastroenterol2016 Oct 01; 7 AB - Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD) in approximately 70% of patients, with ulcerative colitis (UC) being the most common subtype of IBD identified. There is a paucity of data on the optimum management strategy for IBD flares in the post-liver transplant patient, particularly when refractory to conventional treatments. Vedolizumab is a novel gut-specific monoclonal antibody, which has recently been approved for use by National Institute for Health and Care Excellence for moderate-to-severe UC. We present an exemplar case of successful use of vedolizumab in the management of corticosteroid refractory PSC-IBD after liver transplantation.